Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 1/2019

Open Access 01-01-2019 | EM - ORIGINAL

Guidelines for the management of osteoporosis and fragility fractures

Authors: Ranuccio Nuti, Maria Luisa Brandi, Giovanni Checchia, Ombretta Di Munno, Ligia Dominguez, Paolo Falaschi, Carmelo Erio Fiore, Giovanni Iolascon, Stefania Maggi, Raffaella Michieli, Silvia Migliaccio, Salvatore Minisola, Maurizio Rossini, Giuseppe Sessa, Umberto Tarantino, Antonella Toselli, Giovanni Carlo Isaia

Published in: Internal and Emergency Medicine | Issue 1/2019

Login to get access

Abstract

The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIOT).
Literature
1.
NIH Consensus development panel on osteoporosis prevention (2001) Diagnosis and therapy. JAMA 285:785–795CrossRef
2.
Siris ES, Adler R, Bilezikian J et al (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443CrossRefPubMedPubMedCentral
3.
4.
5.
Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98–109CrossRefPubMed
6.
Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526CrossRef
7.
Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin N Am 41:595–611CrossRef
8.
9.
Yu TM, Lin CL, Chang SN, Sung FC, Huang ST, Kao CH (2014) Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study. Mayo Clin Proc 89:888–895CrossRefPubMed
10.
11.
Maggi S, Noale M, Giannini S et al; ESOPO Study (2006) Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int 17:237–244
12.
Svedbom A, Hernlund E, Ivergård M et al (2013) Epidemiology and economic burden of osteoporosis in Italy. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:137CrossRefPubMedPubMedCentral
13.
Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2a):12S–17SCrossRefPubMed
14.
Piscitelli P, Brandi ML, Tarantino U et al (2010) Incidence and socioeconomic burden of hip fractures in Italy: extension study 2003–2005. Reumatismo 62:113–118PubMed
15.
Gimigliano F, Moretti A, Riccio I, Letizia Mauro G, Gimigliano R, Iolascon G (2015) Classification of functioning and assessment of fracture risk of a large Italian osteoporotic population. The physiatric approach to osteoporosis project. Eur J Phys Rehabil Med 51:529–538PubMed
16.
Lapi F, Simonetti M, Michieli R et al (2012) Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 50:85–90CrossRefPubMed
17.
Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum 46:3136–3142CrossRefPubMed
18.
Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368–381CrossRefPubMed
19.
Cavalli L, Guazzini A, Cianferotti L et al (2016) Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign. BMC Musculoskelet Disord 17:396CrossRefPubMedPubMedCentral
20.
Michieli R, Carraro AM (2014) General practitioner and FRAX(®) (computer-based algorithm). Clin Cases Miner Bone Metab 11:120–122PubMedPubMedCentral
21.
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMedPubMedCentral
22.
Lapi F, Bianchini E, Michiel R et al (2017) Assessing risk of osteoporotic fractures in primary care: development and validation of the FRA-HS algorithm. Calcif Tissue Int 100:537–549CrossRef
23.
Rossini M, Adami S, Bertoldo F et al (2016) Linee guida per la diagnosi, la prevenzione e il trattamento dell’osteoporosi. Reumatismo 68:1–42CrossRefPubMed
24.
Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 ISCD position development conference on bone densitometry. J Clin Densitom 16:455–467CrossRefPubMed
25.
Kanis JA, McCloskey EV, Johansson H et al (2013) Scientific advisory board of the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the committee of scientific advisors of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefPubMed
26.
Hans D, Šteňová E, Lamy O (2017) The trabecular bone score (TBS) complements DXA and the FRAX as a fracture risk assessment tool in routine clinical practice. Curr Osteoporos Rep 15:521–531CrossRefPubMed
27.
Høiberg MP, Rubin KH, Hermann AP, Brixen K, Abrahamsen B (2016) Diagnostic devices for osteoporosis in the general population: a systematic review. Bone 92:58–69CrossRefPubMed
28.
Wang YXJ, Santiago FR, Deng M, Nogueira-Barbosa MH (2017) Identifying osteoporotic vertebral endplate and cortex fractures. Quant Imaging Med Surg 7:555–591CrossRefPubMedPubMedCentral
29.
Genant HK, Jergas M (2003) Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 14(Suppl 3):S43–S55CrossRefPubMed
30.
Genant HK, Jergas M, Palermo L et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984–996CrossRefPubMed
31.
Clark EM, Carter L, Gould VC, Morrison L, Tobias JH (2014) Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening. Osteoporos Int 25:953–964CrossRefPubMed
32.
Diacinti D, Guglielmi G, Pisani D et al (2012) Vertebral morphometry by dual-energy X-ray absorptiometry (DXA) for osteoporotic vertebral fractures assessment (VFA). Radiol Med 117:1374–1385CrossRefPubMed
33.
34.
35.
Eastell R, Szulc P (2017) Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 5:908–923CrossRefPubMed
36.
37.
Cheng S, Lyytikäinen A, Kröger H et al (2005) Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10- to 12-year-old girls: a 2-year randomized trial. Am J Clin Nutr 82:1115–1126CrossRefPubMed
38.
Hacker AN, Fung EB, King JC (2012) Role of calcium during pregnancy: maternal and fetal needs. Nutr Rev 70:397–409CrossRefPubMed
39.
40.
Iolascon G, Gimigliano R, Bianco M et al (2017) Are dietary supplements and nutraceuticals effective for musculoskeletal health and cognitive function? A scoping review. J Nutr Health Aging 21:527–538CrossRefPubMed
41.
Lips P, Bouillon R, van Schoor NM et al (2010) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 73:277–285CrossRef
42.
Popovtzer MM, Michael UF, Johnson-Dial KS, Ronstadt C, Nelson D, Ogden DA (1986) Dietary calcium deprivation and secondary hyperparathyroidism in patients treated with chronic dialysis. Miner Electrolyte Metab 12:298–302PubMed
43.
Wallace TC, Frankenfeld CL (2017) Dietary protein intake above the current RDA and bone health: a systematic review and meta-analysis. J Am Coll Nutr 36:481–496CrossRefPubMed
44.
Weaver CM, Gordon CM, Janz KF et al (2016) The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 27:1281–1386CrossRefPubMedPubMedCentral
45.
Adami S, Romagnoli E, Carnevale V et al (2011) Guidelines on prevention and treatment of vitamin D deficiency. Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). Reumatismo 63:129–147CrossRefPubMed
46.
Reid IR, Bolland MJ, Grey A (2014) Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383:146–155CrossRefPubMed
47.
48.
49.
Adami S, Giannini S, Bianchi G et al (2009) Vitamin D status and response to treatment in postmenopausal osteoporosis. Osteoporos Int 20:239–244CrossRefPubMed
50.
51.
Rizzoli R, Boonen S, Brandi ML et al (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29:305–313CrossRefPubMed
52.
Rossini M, Adami S, Viapiana O et al (2012) Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int 91:365–369CrossRefPubMed
53.
Sanders KM, Stuart AL, Williamson EJ et al (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822CrossRefPubMed
54.
Cianferotti L, Cricelli C, Kanis JA et al (2015) The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine 50:12–26CrossRefPubMed
55.
56.
Martyn-St James M, Carroll S (2008) Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 43:521–531CrossRefPubMed
57.
Ma D, Wu L, He Z (2013) Effects of walking on the preservation of bone mineral density in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Menopause 20:1216–1226CrossRefPubMed
58.
Howe TE, Shea B, Dawson LJ et al (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 7:CD000333
59.
Ma C, Liu A, Sun M, Zhu H, Wu H (2016) Effect of whole-body vibration on reduction of bone loss and fall prevention in postmenopausal women: a meta-analysis and systematic review. J Orthop Surg Res 11:24CrossRefPubMedPubMedCentral
60.
Armstrong JJ, Rodrigues IB, Wasiuta T, MacDermid JC (2016) Quality assessment of osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal. Arch Osteoporos 11:6CrossRefPubMed
61.
Parker MJ, Gillespie WJ, Gillespie LD (2006) Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 332:571–574CrossRefPubMedPubMedCentral
62.
Gillespie WJ, Gillespie LD, Parker MJ (2010) Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 10:CD001255
63.
Gosch M, Hoffmann-Weltin Y, Roth T, Blauth M, Nicholas JA, Kammerlander C (2016) Orthogeriatric co-management improves the outcome of long-term care residents with fragility fractures. Arch Orthop Trauma Surg 136:1403–1409CrossRefPubMedPubMedCentral
64.
Yates CJ, Chauchard MA, Liew D, Bucknill A, Wark JD (2015) Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service. J Clin Densitom 18:150–156CrossRefPubMed
65.
66.
Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529CrossRefPubMedPubMedCentral
67.
Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24:393–406CrossRefPubMed
68.
Blain H, Masud T, Dargent-Molina P, Martin FC, Rosendahl E, van der Velde N, Bousquet J, Benetos A, Cooper C, Kanis JA, Reginster JY, Rizzoli R, Cortet B, Barbagallo M, Dreinhöfer KE, Vellas B, Maggi S, Strandberg T; EUGMS Falls and Fracture Interest Group,; International Association of Gerontology and Geriatrics for the European Region (IAGG-ER); European Union of Medical Specialists (EUMS); Fragility Fracture Network (FFN); European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), and; International Osteoporosis Foundation (IOF) (2016) A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. Aging Clin Exp Res 28(4):797–803
69.
Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C, Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 2(16):158CrossRef
70.
Hertz K, Santy-Tomlison J (2018) Fragility Fracture nursing: holistic care and management of the orthogeriatric patient. Perspectives in nursing management and care for older adults. Springer, p 137
71.
Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRefPubMed
72.
Adami S, Bianchi G, Brandi ML et al (2010) Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 28:561–570PubMed
73.
Coleman RE, Rathbone E, Brown JE (2013) Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 9:365–374CrossRefPubMed
74.
Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839CrossRefPubMed
75.
Hodges LA, Connolly SM, Winter J et al (2012) Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm 432:57–62CrossRefPubMed
76.
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed
77.
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed
78.
Giusti A, Bianchi G (2015) Treatment of primary osteoporosis in men. Clin Interv Aging 10:105–115PubMed
79.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69(8):1521–1537CrossRefPubMed
80.
Varenna M, Adami S, Rossini M et al (2013) Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatol Oxf Engl 52:534–542CrossRef
81.
Rossini M, Adami G, Adami S, Viapiana O, Gatti D (2016) Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf 15:1–32CrossRef
82.
Rossini M, Adami S, Viapiana O et al (2012) Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res 27:227–230CrossRefPubMed
83.
Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed
84.
Khan AA, Morrison A, Kendler DL et al (2017) Case-Based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom 20:8–24CrossRefPubMed
85.
Anagnostis P, Paschou SA, Mintziori G et al (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30CrossRefPubMed
86.
Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
87.
Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875–4882CrossRefPubMed
88.
Lipton A, Smith MR, Ellis GK, Goessl C (2012) Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol 6:287–303CrossRefPubMedPubMedCentral
89.
Smith MR, Egerdie B, Hernández Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755CrossRefPubMedPubMedCentral
90.
Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155CrossRefPubMedPubMedCentral
91.
Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703CrossRefPubMed
92.
Obermayer-Pietsch BM, Marin F, McCloskey EV et al; Investigators EUROFORS (2008) Effects of 2 years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600
93.
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Ericson EF (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941CrossRefPubMed
94.
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed
95.
Parreira PCS, Maher CG, Megale RZ, March L, Ferreira ML (2017) An overview of clinical guidelines for the management of vertebral compression fracture: a systematic review. Spine J 17:1932–1938CrossRefPubMed
96.
Aparisi F (2016) Vertebroplasty and kyphoplasty in vertebral osteoporotic fractures. Semin Musculoskelet Radiol 20:382–391CrossRefPubMed
Metadata
Title
Guidelines for the management of osteoporosis and fragility fractures
Authors
Ranuccio Nuti
Maria Luisa Brandi
Giovanni Checchia
Ombretta Di Munno
Ligia Dominguez
Paolo Falaschi
Carmelo Erio Fiore
Giovanni Iolascon
Stefania Maggi
Raffaella Michieli
Silvia Migliaccio
Salvatore Minisola
Maurizio Rossini
Giuseppe Sessa
Umberto Tarantino
Antonella Toselli
Giovanni Carlo Isaia
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 1/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1874-2

Other articles of this Issue 1/2019

Internal and Emergency Medicine 1/2019 Go to the issue

IM - COMMENTARY

Silybin and metabolic disorders

IM - CASE RECORD

Fever, edema, and shortness of breath: the Scrhödinger’s cat paradox displayed on pericardium

IM - REVIEW

Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer

Research Letter to the Editor

Sulphurous mud-bath therapy for treatment of chronic low back pain caused by lumbar spine osteoarthritis

Correction

Correction to: Clinical impact of hospital malnutrition

IM - COMMENTARY

Daylight saving time and circadian rhythms in the neuro-endocrine-immune system: impact on cardiovascular health
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits